Affimed Announces Virtual Annual General Meeting of Shareholders
May 20 2021 - 4:30PM
Heidelberg, Germany, May 20, 2021
– Affimed N.V. (Nasdaq: AFMD), a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, announced today that its 2021
Annual General Meeting of Shareholders (the “Annual Meeting”) will
be held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT). Due to the
continuing COVID-19 pandemic and out of concern for the health and
safety of shareholders and other attendees, the Annual Meeting will
be held virtually and can be followed by visiting
www.virtualshareholdermeeting.com/AFMD2021, in accordance with the
instructions provided in the notice of the meeting.
Shareholders will not be able to attend the Annual Meeting in
person.
The notice and agenda of the Annual Meeting are available on
Affimed’s website at https://www.affimed.com/investors/ under
“Annual Meeting”, as well as the SEC’s website at www.sec.gov.
About Affimed N.V.Affimed (Nasdaq: AFMD) is a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer by actualizing the
untapped potential of the innate immune system. The company’s
proprietary ROCK® platform enables a tumor-targeted approach to
recognize and kill a range of hematologic and solid tumors,
enabling a broad pipeline of wholly-owned and partnered single
agent and combination therapy programs. The ROCK platform
predictably generates customized innate cell engager (ICE®)
molecules, which use patients’ immune cells to destroy tumor cells.
This innovative approach enabled Affimed to become the first
company with a clinical-stage ICE®. Headquartered in Heidelberg,
Germany, with offices in New York, New York, Affimed is led by an
experienced team of biotechnology and pharmaceutical leaders united
by a bold vision to stop cancer from ever derailing patients’
lives. For more about the company’s people, pipeline and partners,
please visit: www.affimed.com. Investor Relations
ContactAlexander FudukidisHead of Investor
Relationsa.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024